Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019158 (
hepatitis
)
30,205
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
400 unselected liver biopsies were stained with
aldehyde
-thionin (AT) and examined for ground-glass hepatocytes (GGH). 1) AT-positive GGH were found in about half of all HBSAg-positive patients but were never seen in HBSAg-negative patients. 2) AT-positive GGH were observed in healthy HBSAg carriers and in all forms of chronic hepatitis but never in acute HBSAg-positive
hepatitis
. 3) AT-negative GGH were occasionally seen in HBSAg-negative patients under drug treatment. 4) Ultrastructurally GGH showed proliferation of smooth endoplasmic reticulum which only in AT-positive GGH contained filaments, 20-25 nm in diameter, within its cisternae.
...
PMID:Ground-glass hepatocytes in unselected liver biopsies. ultrastructure and relationship to hepatitis B surface antigen. 5 36
"Gigasept" is a highly efficient chemical disinfectant on the basis of succine dialdehyde and form
aldehyde
. The virucidal capacity was assayed in the suspension test procedure with different representative RNA and DNA viruses with and without an envelope, such as polio wild virus type I, coxsackie virus type B 3, adeno virus type 3, herpes virus type ) and vaccinia virus. Parameter for disinfectant activity was the virus inactivation kinetic, i. e. interdependence of titer reduction vs. disinfectant concentration and disinfectant contact time. A "minimal disinfection" was defined as a greater than or equal to 99.9% virus inactivation. A "disinfection per definitionem" must gain a titer reduction of greater than or equal to 10(3) ID 50 and absence of virus. According to these criteria all virus strains were inactivated by Gigasept regardless of absence or presence of serum, which was tested in a concentration of 40% calf serum. Disinfection per definitionem was achieved with Gigasept concentrations of 3% after 60 min. or 5% after 30 min. except for enteroviruses. This group of viruses has to be disinfected with a 10% solution for 4 hours or with a 5% solution overnight. Gigasept, on the basis of these results, can be classified as a highly effective virucidal disinfectant. As to the
hepatitis
virus group however, no data so far are available. An enterovirus - disinfection procedure is recommended in
hepatitis
risk areas, as long as test systems for
hepatitis
viruses are not developed.
...
PMID:[Virucidal activity of the disinfectant "gigasept" against different enveloped and non-enveloped RNA-and DNA-viruses, pathogenic for men. I. Investigation in the suspension test (author's transl)]. 17 45
The histopathology of acute and chronic infections associated with viral hepatitis is reviewed and illustrated. Particular attention is directed to changes that help to differentiate chronic persistent from chronic active viral hepatitis. Features that help to identify the intravenous drug abuser who has
hepatitis
, whether acute or chronic, include the presence of particulate birefringent material (usually talc) in reticuloendothelial cells, as well as tissue eosinophilia. Ground-glass hepatocytes are characteristic of the HBAg carrier. They may be present in chronic persistent and chronic active hepatitis and in cirrhotic livers with or without hepatocellular carcinoma. Ground-glass cells which contain the surface component of the HBAg, can be stained specifically by a number of stains that include
aldehyde
fuchsin and orcein. The cirrhotic liver of the HBAg-seropositive patient may show liver-cell dysplasia, a premalignant change.
...
PMID:Light microscopic morphology of viral hepatitis. 80 46
The so-called novel inclusion body (NIB) is an intrahepatocytic structure which is frequently observed in human cirrhotic liver. It resembles very much to, but definitely differs from Hepatitis B surface antigen (HBsAg) morphologically. The age distribution of liver cirrhosis cases positive for NIB is similar to that positive for HBsAg, except for an existence of a time lag in mean age. One of the best staining methods to demonstrate NIB, for example, is to exhibit it as a reddish body stained by Luna, with a contrast of HBsAg counterstained purple in color by
aldehyde
fuchsin after thiosulfation. Electron microscopy of the liver obtained from a patient, negative for both HBsAg and Hepatitis B e antigen (HBeAg) but positive for Hepatitis B core antibody (HBcAb) and Hepatitis B surface antigen antibody (HBsAb) clinically, revealed some unfamiliar, tubular and cisternal arrays showing a network pattern and ring-shaped structure at the site exactly corresponding to NIB localization. These are considered to have been induced from the endoplasmic reticulum by an unknown agent, for which non A non B
hepatitis
virus (NANBV) is rationally postulated as one of the possibilities. A close relation between NIB and NANBV is highly suspected because of much similarities in histology, histochemistry, age distribution, and electron microscopy. The true nature of NANBV should be rescrutinized, especially in relation with Hepatitis B virus infection, since NIB is quite often observed also in cirrhotic liver positive for HBsAg.
...
PMID:A study on so-called novel inclusion body in human hepatocyte. 241 47
Acetaldehyde
in non-toxic doses (15.6 micrograms per start) causes in the inhibition test of the migration of leucocytes an inhibition of the migration in 6/13 of the patients with alcoholic hepatitis, a stimulation of the migration in 6/11 of alcohol cirrhoses. Healthy (n = 16) persons, patients with alcoholic fatty degeneration of the liver (n = 3) as well as non-alcoholic liver diseases (chronic persisting
hepatitis
, n = 11; chronic active hepatitis, n = 8, cirrhosis, n = 7) did not show this cellular immune reagibility. The inhibition of the migration and the stimulation of the migration, respectively, might develop by hapten autoantigen complexes (altered cytoskeleton?) with release of the factors of inhibition of migration and stimulation of migration, in which case the role of a hapten belongs to acetaldehyde. The results of the tests did not correlate with functional and histological findings of the liver, with the actual consumption of alcohol and also not with haptoglobin phaenotypes. When it is postulated that by acetaldehyde also the release of further lymphokines is mediated, origin and progression of alcoholic hepatitis and alcoholic cirrhosis might be explained immunopathogenetically.
...
PMID:[Acetaldehyde-induced leukocyte migration inhibition in alcoholic liver diseases]. 712 38
Acetaldehyde
, the first metabolite of ethanol, is capable to bind various proteins followed by the formation of acetaldehyde adducts. This condensate is supposed to act as a neoantigen. We have recently demonstrated the appearance of acetaldehyde adducts in liver of experimental animals after chronic ethanol treatment, and we produced an experimental
hepatitis
in guinea pig by immunization with acetaldehyde adducts and treatment with free access to ethanol. However the structure of acetaldehyde adducts and its characteristics are still vague. To elucidate the binding site of anti-adducts antibody against the epitope on adducts, we established a cell line of hybridoma producing monoclonal antibody. This monoclonal antibody recognized protein condensate modified with high concentration of acetaldehyde (1-10 mM) but not those modified with low concentration of it (20-200 microM), whereas the polyclonal antibody produced by conventional method recognized both of them. Using the affinity-purified adducts by monoclonal or polyclonal antibody-liganded column, we examined the antibody titers by ELISA. The elevation of antibody titer was more specific in chronic alcoholics, especially in patients with hepatic inflammatory change, when antibody was measured against the adducts purified by monoclonal antibody than against the adduct purified by polyclonal antibody. Namely, there exist different types of antibody according to the concentration of acetaldehyde to form the adducts. The concentration of acetaldehyde is thought to be much greater in the liver of alcoholics compared to the patient with non alcoholic liver disease. Actually we have immunohistochemically detected the adduct related to high concentration of acetaldehyde in the liver specimen of alcoholics. In conclusion, the appearance of adduct related to high concentration of acetaldehyde and the acquisition of immunity against it appear to be a characteristic feature in alcoholics with hepatic inflammation. Therefore, evaluation of circulating antibodies against protein epitope related to high concentration of acetaldehyde is helpful to know conditions of such types of liver disease seen in alcoholics.
...
PMID:[Immune response against protein epitopes modified with acetaldehyde and its clinical significance in alcoholic liver diseases]. 751 Apr 76
Caffeic acid has been reported to have activity on xanthine oxidase inhibition which is related to several diseases, e.g. gout,
hepatitis
and tumors. Based on this study, the alpha, beta-unsaturated COOH moiety in the molecule of caffeic acid plays a very important role on the xanthine oxidase inhibition because hydrocaffeic acid was inactive and the activities of coniferyl
aldehyde
and coniferyl alcohol were reduced as compared with ferulic acid. Moreover, chlorogenic acid showed a weaker activity than caffeic acid. On the other hand, the phenolic OH group present in the molecule of caffeic acid makes an important contribution to the activity, e.g. transcinnamic acid in which the absence of the phenolic OH group in the structure reduced its activity as compared with caffeic acid. Ferulic acid, isoferulic acid and 3,4-dimethoxy cinnamic acid also had reduced activity due to the methoxy groups replacing the phenolic OH group in the structures. However, m-coumaric acid displayed the strongest activity (IC50 = 63.31 microM) and induced uncompetitive inhibition with respect to the substrate xanthine (Ki = 21.568 microM). Caffeic acid (IC50 = 74.6 microM) showed the second strongest activity, followed by p-coumaric acid (IC50 = 111.09 microM).
...
PMID:Structure-activity relationship of caffeic acid analogues on xanthine oxidase inhibition. 764 46
An increasing number of studies support the involvement of free radical-mediated oxidative reactions in the pathogenesis of tissue injury following ischemia reperfusion. In particular, a condition of oxidative stress is evident in patients with circulatory shock, a disease process often complicated by progressive organ failure sustained by inflammatory reactions. In all shock patients without signs of organ failure, a consistent increase of intermediate and final products of lipid peroxidation (lipid peroxides and aldehydes respectively) was observed. Impairment of the redox equilibrium in the tissues of these patients was confirmed by a significant reduction of glutathione and vitamin E hematic concentrations. Moreover, a selective increase of plasma
aldehyde
-protein adducts, actual proof of oxidative damage of macromolecules, is only present in the shock patients who, in addition, show hepatic cytolysis (ischemic
hepatitis
) as estimated by plasma levels of LDH5 isoenzyme. Aldehyde adducts well mark the progression of the disease towards multiple organ failure. Finally, the good statistical correlation between
aldehyde
-modified proteins and LDH5, as well as their distinct behaviour in control and ischemic
hepatitis
, support the involvement of oxidative damage in the expression and worsening of circulatory shock.
...
PMID:Oxidative stress in the development of human ischemic hepatitis during circulatory shock. 798 28
We examined age-related changes in the protein and the mRNA expression of aldose reductase in livers of Long-Evans with a cinnamon-like color (LEC) rats, which develop hereditary
hepatitis
and hepatoma with aging, using Long-Evans with an agouti color rats as controls. The levels of the protein and mRNA of aldose reductase increased after 20 weeks, at the stage of acute hepatitis, and were maintained at 60 weeks of age, while those of aldehyde reductase seemed to be constant at all ages. The expression of aldose reductase was marked in cancerous lesions in hepatoma-bearing LEC rat liver compared to uninvolved surrounding tissues. These results indicated that elevation of aldose reductase accompanied hepatocarcinogenesis and may be related to the acquisition of immortality of the cancer cells through detoxifying cytotoxic
aldehyde
compounds.
...
PMID:Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma. 864 63
Felbamate demonstrates a unique therapeutic profile and often results in seizure control when other agents fail. Its use has been associated with risks for aplastic anaemia and hepatic failure. A number of confounding factors makes the actual incidence rate for each adverse effect difficult to determine. However, certain risk factors are common in reported cases. In order to minimise the risk, at the present time, it is necessary to rely on the clinical profile of the patients reporting these adverse effects. The patient reporting aplastic anaemia is usually female, Caucasian, and an adult. The dose did not appear to be a factor and the time to onset of aplastic anaemia was less than 1 year for all patients. Concomitant medications and diseases may play an important role. Patients with reported aplastic anaemia generally had a history of a serious allergy or toxicity to other anticonvulsants and/or a background of having had a cytopenia due to other anticonvulsants, and a diagnosis or serological evidence of concomitant immune disorder. The demographics associated with hepatic failure are less well defined. Patients were also predominantly female, were equally divided among adult and paediatric patients, and had a broad range of time to presentation of hepatotoxicity following felbamate therapy. Concomitant medications again play an important role with, in this case, valproic acid (sodium valproate), phenytoin and carbamazepine being the most frequent. In 50% of the population, hepatic failure was not felt to be due to felbamate but associated with confounding factors including status epilepticus, paracetamol (acetaminophen) toxicity,
hepatitis
and shock liver. Initial research has failed to provide a diagnostic indicator. However, work on a potential intermediate felbamate metabolite has suggested the formation of a reactive
aldehyde
whose end products have been detected in the urine of felbamate treated patients. Until these data are confirmed, the medical history, clinical picture, and laboratory testing, should be used to identify patients at risk. The risks for toxicity with felbamate should be evaluated before starting treatment. In addition, liver function tests and complete blood count (CBC) prior to therapy and at clinically rational intervals should be conducted. Patients must be educated in the likely prodromal symptoms of potential marrow/liver toxicity. Felbamate is too valuable an anticonvulsant to be relegated to the therapeutic scrap heap. With monitoring, patient education, and continued research to further elucidate risk factors, felbamate can be a viable therapeutic agent for patients with epilepsy.
...
PMID:Felbamate in epilepsy therapy: evaluating the risks. 1048 99
1
2
Next >>